EBO Stock Overview
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand.
EBOS Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$37.75|
|52 Week High||NZ$44.30|
|52 Week Low||NZ$33.87|
|1 Month Change||-1.05%|
|3 Month Change||-3.23%|
|1 Year Change||7.70%|
|3 Year Change||51.91%|
|5 Year Change||115.84%|
|Change since IPO||1,563.47%|
Recent News & Updates
Does EBOS Group (NZSE:EBO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
EBOS Group (NZSE:EBO) Will Pay A Larger Dividend Than Last Year At A$0.5116
EBOS Group Limited's ( NZSE:EBO ) dividend will be increasing from last year's payment of the same period to A$0.5116...
|EBO||NZ Healthcare||NZ Market|
Return vs Industry: EBO exceeded the NZ Healthcare industry which returned -21.7% over the past year.
Return vs Market: EBO exceeded the NZ Market which returned -16.8% over the past year.
|EBO Average Weekly Movement||2.6%|
|Healthcare Industry Average Movement||3.8%|
|Market Average Movement||3.8%|
|10% most volatile stocks in NZ Market||8.0%|
|10% least volatile stocks in NZ Market||2.7%|
Stable Share Price: EBO is less volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: EBO's weekly volatility (3%) has been stable over the past year.
About the Company
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services.
EBOS Group Fundamentals Summary
|EBO fundamental statistics|
Is EBO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EBO income statement (TTM)|
|Cost of Revenue||AU$9.50b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.07|
|Net Profit Margin||1.89%|
How did EBO perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is EBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EBO?
Other financial metrics that can be useful for relative valuation.
|What is EBO's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does EBO's PE Ratio compare to its peers?
|EBO PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
RYM Ryman Healthcare
SUM Summerset Group Holdings
FPH Fisher & Paykel Healthcare
ARV Arvida Group
EBO EBOS Group
Price-To-Earnings vs Peers: EBO is expensive based on its Price-To-Earnings Ratio (31x) compared to the peer average (11.6x).
Price to Earnings Ratio vs Industry
How does EBO's PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: EBO is expensive based on its Price-To-Earnings Ratio (31x) compared to the Global Healthcare industry average (17.1x)
Price to Earnings Ratio vs Fair Ratio
What is EBO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||31x|
|Fair PE Ratio||19.7x|
Price-To-Earnings vs Fair Ratio: EBO is expensive based on its Price-To-Earnings Ratio (31x) compared to the estimated Fair Price-To-Earnings Ratio (19.7x).
Share Price vs Fair Value
What is the Fair Price of EBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EBO (NZ$37.75) is trading below our estimate of fair value (NZ$60.71)
Significantly Below Fair Value: EBO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is EBOS Group forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EBO's forecast earnings growth (11.9% per year) is above the savings rate (2.1%).
Earnings vs Market: EBO's earnings (11.9% per year) are forecast to grow faster than the NZ market (5.9% per year).
High Growth Earnings: EBO's earnings are forecast to grow, but not significantly.
Revenue vs Market: EBO's revenue (5.7% per year) is forecast to grow faster than the NZ market (5.6% per year).
High Growth Revenue: EBO's revenue (5.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EBO's Return on Equity is forecast to be low in 3 years time (13.3%).
Discover growth companies
How has EBOS Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EBO has high quality earnings.
Growing Profit Margin: EBO's current net profit margins (1.9%) are lower than last year (2%).
Past Earnings Growth Analysis
Earnings Trend: EBO's earnings have grown by 10.4% per year over the past 5 years.
Accelerating Growth: EBO's earnings growth over the past year (9.3%) is below its 5-year average (10.4% per year).
Earnings vs Industry: EBO earnings growth over the past year (9.3%) underperformed the Healthcare industry 12.7%.
Return on Equity
High ROE: EBO's Return on Equity (9.4%) is considered low.
Discover strong past performing companies
How is EBOS Group's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EBO's short term assets (A$3.1B) exceed its short term liabilities (A$2.5B).
Long Term Liabilities: EBO's short term assets (A$3.1B) exceed its long term liabilities (A$1.6B).
Debt to Equity History and Analysis
Debt Level: EBO's net debt to equity ratio (39.3%) is considered satisfactory.
Reducing Debt: EBO's debt to equity ratio has increased from 52% to 64% over the past 5 years.
Debt Coverage: EBO's debt is not well covered by operating cash flow (18.1%).
Interest Coverage: EBO's interest payments on its debt are well covered by EBIT (12.1x coverage).
Discover healthy companies
What is EBOS Group current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|EBOS Group Dividend Yield vs Market|
|Company (EBOS Group)||2.6%|
|Market Bottom 25% (NZ)||2.9%|
|Market Top 25% (NZ)||6.0%|
|Industry Average (Healthcare)||2.6%|
|Analyst forecast in 3 Years (EBOS Group)||3.5%|
Notable Dividend: EBO's dividend (2.6%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.85%).
High Dividend: EBO's dividend (2.6%) is low compared to the top 25% of dividend payers in the NZ market (6.04%).
Stability and Growth of Payments
Stable Dividend: EBO's dividends per share have been stable in the past 10 years.
Growing Dividend: EBO's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (76.8%), EBO's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (102.6%), EBO's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity serve...
CEO Compensation Analysis
|John Cullity's Compensation vs EBOS Group Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||AU$6m||AU$1m|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$4m||AU$1m|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$4m||AU$1m|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$2m||AU$1m|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||AU$1m||AU$287k|
Compensation vs Market: John's total compensation ($USD3.80M) is above average for companies of similar size in the NZ market ($USD1.88M).
Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.
Experienced Management: EBO's management team is considered experienced (4.4 years average tenure).
Experienced Board: EBO's board of directors are considered experienced (9.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|11 Jan 22||SellNZ$48,279||Nicholas Dowling||Individual||1,198||NZ$40.30|
|13 Dec 21||BuyNZ$57,701||Tracey Batten||Individual||1,500||NZ$38.47|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
EBOS Group Limited's employee growth, exchange listings and data sources
- Name: EBOS Group Limited
- Ticker: EBO
- Exchange: NZSE
- Founded: 1922
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: NZ$7.151b
- Shares outstanding: 189.44m
- Website: https://www.ebosgroup.com
Number of Employees
- EBOS Group Limited
- 737 Bourke Street
- Level 7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EBO||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jun 1999|
|EBOS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1999|
|EBO||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 1999|
|EBO||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 1999|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.